The estimated Net Worth of Charles Lee Sr Nuzum is at least $53.2 Tisíc dollars as of 25 September 2023. Charles Nuzum owns over 10,000 units of Predictive Oncology stock worth over $22,831 and over the last 4 years Charles sold POAI stock worth over $30,400.
Charles has made over 2 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently Charles sold 10,000 units of POAI stock worth $30,400 on 25 September 2023.
The largest trade Charles's ever made was buying 200,000 units of Predictive Oncology stock on 20 May 2022 worth over $62,000. On average, Charles trades about 11,667 units every 27 days since 2020. As of 25 September 2023 Charles still owns at least 24,033 units of Predictive Oncology stock.
You can see the complete history of Charles Nuzum stock trades at the bottom of the page.
Charles's mailing address filed with the SEC is 23, Brookline Drive, Dewitt, Novato, Marin County, California, 94949, United States of America.
Over the last 5 years, insiders at Predictive Oncology have traded over $30,944 worth of Predictive Oncology stock and bought 417,770 units worth $148,589 . The most active insiders traders include Carl I. Schwartz, J Melville Engle a Charles Lee Sr Nuzum. On average, Predictive Oncology executives and independent directors trade stock every 71 days with the average trade being worth of $29,495. The most recent stock trade was executed by Robert L Myers on 25 September 2023, trading 1,667 units of POAI stock currently worth $1,584.
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Predictive Oncology executives and other stock owners filed with the SEC include: